Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer.

MLA

Besse, B., et al. “Phase Ib Safety and Pharmacokinetic Study of Volociximab, an Anti-Α5β1 Integrin Antibody, in Combination with Carboplatin and Paclitaxel in Advanced Non-Small-Cell Lung Cancer.” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 24, no. 1, Jan. 2013, pp. 90–96. EBSCOhost, https://doi.org/10.1093/annonc/mds281.

APA

Besse, B., Tsao, L. C., Chao, D. T., Fang, Y., Soria, J.-C., Almokadem, S., & Belani, C. P. (2013). Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 24(1), 90–96. https://doi.org/10.1093/annonc/mds281

Chicago

Besse, B, L C Tsao, D T Chao, Y Fang, J-C Soria, S Almokadem, and C P Belani. 2013. “Phase Ib Safety and Pharmacokinetic Study of Volociximab, an Anti-Α5β1 Integrin Antibody, in Combination with Carboplatin and Paclitaxel in Advanced Non-Small-Cell Lung Cancer.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 24 (1): 90–96. doi:10.1093/annonc/mds281.